TREMFYA – Use in Adult Patients with Psoriasis or Psoriatic Arthritis and Comorbid Renal Impairment – Real World Evidence

SUMMARY  

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Please refer to local labeling for relevant information regarding the use of TREMFYA in adult patients with renal impairment.
• A case report is summarized below regarding an adult patient with renal impairment who received TREMFYA for psoriasis (PsO).¹
• The literature search did not identify any relevant citations pertaining to this topic in adult patients with psoriatic arthritis (PsA).

CLINICAL DATA

Madireddy et al (2021)¹ reported a case of an 86-year-old female patient with history of chronic kidney disease, hypertension, renal cell carcinoma with left nephrectomy, and congestive heart failure, who was being treated with TREMFYA for PsO since 2018.

• She had received a TREMFYA injection one week prior to presenting to the hospital.
• The patient arrived at the hospital with worsening bilateral lower extremity (LE) edema and acute kidney injury, with an elevated serum creatinine (SCr) of 3.75 mg/dL and serum albumin was reported within normal limits at 3.5 g/dL.
• Three weeks prior to presentation, her SCr was elevated but reported as stable at 1.77 mg/dL.
• During the hospital stay, urinalysis showed proteinuria and hematuria, with an elevated spot urine total protein-to-urine creatinine ratio of 13.7 from 1.6 recorded 4 months prior to presentation.
• She initially received diuretic treatment for LE edema.
• Kidney biopsy revealed collapsing glomerulopathy and severe acute tubular injury.
• The patient’s SCr rapidly worsened to 7.98 mg/dL requiring treatment with hemodialysis (as of this report, the Authors’ noted the patient remained dialysis dependent).
• The patient was also started on daily high dose oral corticosteroid therapy.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 21 August 2026.